{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:16:34Z","timestamp":1789748194402,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ctrv.2024.102726","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T16:22:43Z","timestamp":1711729363000},"page":"102726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["First-line combination treatment with PARP and androgen receptor\u2013signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States"],"prefix":"10.1016","volume":"126","author":[{"given":"Rana R.","family":"McKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Dunshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Devgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102726_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102726_b0010","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/cncr.31549","article-title":"Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics","volume":"124","author":"Negoita","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102726_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102726_b0020","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/biomedicines9091247","article-title":"Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Henriquez","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2024.102726_b0025","series-title":"Cancer Facts & Figures 2023","author":"American Cancer Society","year":"2022"},{"key":"10.1016\/j.ctrv.2024.102726_b0030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djad020","article-title":"Changes in survival in de novo metastatic cancer in an era of new medicines","volume":"115","author":"Luyendijk","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102726_b0035","unstructured":"Healthcare Quality Improvement Partnership (HQIP). Patient and Tumour Characteristics Associated with Metastatic Prostate Cancer at Diagnosis in England. UK: HQIP; 2022."},{"key":"10.1016\/j.ctrv.2024.102726_b0040","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102726_b0045","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2024.102726_b0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5694\/mja2.51722","article-title":"Modern paradigms for prostate cancer detection and management","volume":"217","author":"Williams","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.ctrv.2024.102726_b0055","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J Mens Health"},{"key":"10.1016\/j.ctrv.2024.102726_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ctrv.2024.102726_b0065","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102726_b0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2023.41.6_suppl.81","article-title":"Characterization and survival benefit of drugs approved for metastatic prostate cancer","volume":"41","author":"Benjamin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0075","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2024.102726_b0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2024.102726_b0085","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2024.102726_b0090","doi-asserted-by":"crossref","unstructured":"Kaye D.R, Khilfeh I, Muser E, Morrison L, Holiday C, Kinkead F, et al. Economic burden pre- and post-progression to metastatic castration-resistant prostate cancer (mCRPC) and after first-line mCRPC therapy initiation. Poster presented at: ISPOR; May 7-10, 2023; Boston, MA. Poster RWD88.","DOI":"10.1016\/j.jval.2023.03.2117"},{"key":"10.1016\/j.ctrv.2024.102726_b0095","article-title":"Prospective comprehensive genomic profiling of primary and metastatic prostate tumors","volume":"3","author":"Chung","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0100","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102726_b0105","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102726_b0110","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102726_b0115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2024.102726_b0120","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/JCO.2023.41.16_suppl.5003","article-title":"Presence of somatic\/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status","volume":"41","author":"Olmos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0125","unstructured":"U.S. Food and Drug Administration. RUBRACA\u00ae (rucaparib) prescribing information. Revised June 2022."},{"key":"10.1016\/j.ctrv.2024.102726_b0130","unstructured":"U.S. Food and Drug Administration. LYNPARZA\u00ae (olaparib) prescribing information. November 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0135","unstructured":"U.S. Food and Drug Administration. TALZENNA\u00ae (talazoparib) prescribing information. June 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0140","unstructured":"U.S. Food and Drug Administration. AKEEGATM (niraparib and abiraterone acetate) tablets, for oral use. 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0145","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102726_b0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102726_b0165","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0170","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102726_b0175","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102726_b0180","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102726_b0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2024.102726_b0195","doi-asserted-by":"crossref","first-page":"eaax6367","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2024.102726_b0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102726_b0205","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ctrv.2024.102726_b0210","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102726_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102726_b0225","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y","article-title":"Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer","volume":"25","author":"Hyytinen","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2024.102726_b0230","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","article-title":"Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression","volume":"26","author":"Chakraborty","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102726_b0235","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/fon-2021-0811","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0240","doi-asserted-by":"crossref","unstructured":"Fizazi K., Azad A.A., Matsubara N., Carles J., Fay A.P., De Giorgi U., et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 2023;Online ahead of print. DOI: 10.1038\/s41591-023-02704-x.","DOI":"10.1038\/s41591-024-02835-9"},{"key":"10.1016\/j.ctrv.2024.102726_b0245","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm)","volume":"42","author":"Hussain","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-023-00676-0","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","author":"Tuffaha","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2024.102726_b0260","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102726_b0265","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer Version 4.2023. 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2024.102726_b0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102726_b0280","doi-asserted-by":"crossref","first-page":"1054497","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"12","author":"Kwan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.22465\/juo.234600060003","article-title":"The current state and future of plasma cell-free DNA analysis in urologic malignancies","volume":"21","author":"Akamatsu","year":"2023","journal-title":"J Urol Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0290","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102726_b0295","unstructured":"U.S. Food and Drug Administration. XTANDI\u00ae (enzalutamide) prescribing information. November 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0300","unstructured":"ClinicalTrials.gov. Abiraterone\/Prednisone, olaparib, or abiraterone\/prednisone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects. 2023."},{"key":"10.1016\/j.ctrv.2024.102726_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102726_b0310","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ctrv.2024.102726_b0315","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1200\/JCO.2023.41.16_suppl.5053","article-title":"Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study","volume":"41","author":"Azad","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0320","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the European Prostate Cancer Registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0325","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","author":"Agarwal","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.9","volume":"39","author":"Rathkopf","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0335","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2023.41.6_suppl.190","article-title":"TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations","volume":"41","author":"Markowski","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102726_b0340","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/cancers14112696","article-title":"Current status and future perspective on the management of lymph node-positive prostate cancer after radical prostatectomy","volume":"14","author":"Shiota","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102726_b0345","doi-asserted-by":"crossref","first-page":"e389516","DOI":"10.1200\/EDBK_389516","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:42:16Z","timestamp":1715668936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":69,"alternative-id":["S0305737224000537"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102726","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line combination treatment with PARP and androgen receptor\u2013signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102726"}}